Acrivon CLO granted 129,760 stock options

Miller Mary reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Miller Mary reported acquisition or exercise transactions in this Form 4 filing.

Acrivon Therapeutics reported that Chief Legal Officer Mary Miller received a grant of stock options covering 129,760 shares of common stock on March 1, 2026. According to the vesting terms, 25% of these options vest on March 1, 2027, with the remaining options vesting in 36 substantially equal monthly installments thereafter, all conditioned on her continued service through each vesting date.

Insider Trade Summary

Grant/Award: 129,760 shares

Grant/Award 1 txn

Insider Miller Mary

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	129,760	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 129,760 contracts (Direct)

Footnotes (1)

1. F1. Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Acrivon Therapeutics (ACRV) report for Mary Miller?

Acrivon Therapeutics reported that Chief Legal Officer Mary Miller received a grant of stock options. The Form 4 lists a single acquisition of 129,760 stock options as a grant or award, with no sales transactions reported in this filing.

How many stock options were granted to Mary Miller in the latest ACRV Form 4?

Mary Miller was granted stock options for 129,760 shares of Acrivon Therapeutics common stock. The Form 4 shows this entire amount as a single derivative award, with 129,760 options reported as owned directly following the transaction.

What is the vesting schedule for Mary Miller’s 129,760 Acrivon stock options?

The vesting schedule provides that 25% of the options vest on March 1, 2027. The remaining shares subject to the option then vest in 36 substantially equal monthly installments, subject to Mary Miller’s continuous service through each vesting date.

Does the ACRV Form 4 show Mary Miller buying or selling Acrivon shares on the market?

The Form 4 does not show open-market buying or selling by Mary Miller. It reports a single transaction coded “A”, described as a grant, award, or other acquisition of stock options, rather than a market purchase or sale of common shares.

What role does Mary Miller hold at Acrivon Therapeutics in this Form 4?

Mary Miller is identified as the Chief Legal Officer of Acrivon Therapeutics. The Form 4 lists her as an officer, with the stock option grant reported as direct ownership in her capacity as a company executive.

Are Mary Miller’s ACRV stock options subject to any service conditions?

Yes, the vesting of Mary Miller’s options depends on her continued service. The footnote states that vesting on March 1, 2027 and each of the 36 monthly installments thereafter is conditioned on her continuous service through each respective vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 04:19 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Mary

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.51	03/01/2026		A		129,760		(1)	02/29/2036	Common Stock	129,760	$0	129,760	D

Explanation of Responses:

1. Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.